Diverse young girls smiling .png
NEW-isd-Spira-Logo-Txt-symbol-left-sidef
 

Technology

ISD-Immunotech is developing a first-in-class therapy to treat the most severe Systemic lupus erythematosus (SLE)  patients. The therapy works by dampening the action of an intracellular protein called STimulator of INterferon Genes (STING). STING is part of the innate immune system, the body’s first line of defense against pathogen invaders like bacteria and viruses. When activated, STING ramps up production of inflammatory proteins called interferons and cytokines. STING overactivity has recently been linked to severe SLE. SLE is an autoimmune disease that can affect any organ of the body including the skin, joints, heart, kidneys, lungs, nervous system and others. As immune cells attack the body, inflammation, scarring, and permanent damage ensue, leading to worsened function and sometimes even organ failure and death.

nephritis IHC.jpg

Today there is no drug that can significantly alter the disease for severe SLE patients.  ISD has shown that our lead prevents the development of SLE in a mouse model of SLE and reduces the interferon signature in a benchtop test of human patient blood samples.  ISD-Immunotech's approach is unique in targeting STING, a new molecular target for SLE, eliciting dampening of multiple events implicated in SLE including IFN-1 levels, other cytokines and apoptosis for broader efficacy. Furthermore, ISD seeks to reduce the complexity of SLE clinical development by using a benchtop test to pre-select severe patients who respond the therapy instead of targeting the heterogenous SLE population. 

SLE hand.jpg
 

Board of Directors

Ingelise Saunders Chairman of the Board

  • Grey LinkedIn Icon
Lars_Østergaard_Foto.jpg_edited.png

Lars Jørgen Østergaard 

Founder and Board Member 

Aarhus university_edited.jpg
Jeroen Bakker 2018_2_edited.jpg

Jeroen Bakker 

Board Member

  • Grey LinkedIn Icon
Stephan Christgau_edited.jpg

Stephan Christgau
Board Member

  • Grey LinkedIn Icon
Hans Van Eenennaam-bw.jpg

Hans Van Eenennaam
Board Member

  • Grey LinkedIn Icon

The Team

Executive Management

Ingelise Saunders
CEO

  • Grey LinkedIn Icon

Kristian Hansen

CDO

  • Grey LinkedIn Icon
Claus_Hansen_edited.png

Claus Hansen

CFO

  • Grey LinkedIn Icon

    Scientific Advisory Board

    Søren_Paludan.jpg_edited.png

    Prof. Søren Riis Paludan

    SAB Chairman

    Professor in Molecular Virology and immunology, 

    Dept. Biomedicine, Aarhus University, Denmark

    cropped-AU_logo_1_AU_edited.png

    Dr. Prapaporn Pisitkun

     

     

    Associate Professor at Faculty of Medicine Ramathibodi 

    • Grey LinkedIn Icon

    Prof. Betty Diamond

    Professor & Head, Center for Autoimmune, Musculoskeletal & Hematopoietic Diseases 

    The Feinstein Institute for Medical Research

    • Feinstein Institute_edited

    Dr. Harsukh Parmar, MD

    Former Executive level leadership positions at Pfizer, Roche, AstraZeneca & Merck Kga and expert in autoimmune disease.

    • Grey LinkedIn Icon

    Publications

    Scientific Papers 

    Articles by Betty Diamond

    Articles by Søren Riis Paludan

     
     

    About iSD Immunotech

    iSD Immunotech is a spin-out of Aarhus University, Denmark and is dedicated to developing the first efficacious treatment - a targeted molecular therapy for the most severe SLE patients.

    iSD---Logo-replacement-left.png

    Contact Us

    To learn more, don't hesitate to get in touch! 

    Thanks for submitting!